Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, reports financial results for the three and nine months ended September 30, 2025 and recent developments. https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg Financial Summary – Third Quarter 2025 vs. Third Quarter 2024 — Cash and cash equivalents, short term […]